Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | F12 | P00748 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668498 | 0.97 | F2 (0.46) | F2F10F12F7F3 | |
| SCHEMBL19608218 | 0.79 | PRSS1 (0.58) | PRSS1PRSS2PRSS3MAPTHDAC8 | |
| Iodide SCHEMBL7118811 | 0.76 | MAPT (0.47) | KMT2AMEN1CA1CA2ALDH1A1 | |
| Iodide SCHEMBL3826457 | 0.76 | LMNA (0.46) | KMT2AMEN1CA1CA2ALDH1A1 | |
| Iodide SCHEMBL7079741 | 0.76 | HDAC8 (0.48) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL24761126 | 0.73 | F2 (0.42) | F2F10F12F7F3 | |
| SCHEMBL8388749 | 0.73 | — | — | |
| SCHEMBL1981632 | 0.73 | MAPT (0.48) | KMT2AMEN1CA1CA2ALDH1A1 | |
| SCHEMBL13933397 | 0.73 | LMNA (0.48) | KMT2AMEN1CA1CA2ALDH1A1 | |
| Iodide SCHEMBL6400498 | 0.73 | NPC1 (0.50) | KMT2AMEN1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023052772-A1 | AMIDO DERIVATIVES FOR USE IN THE TREATMENT OF RNA VIRAL INFECTIONS | UNIVERSITY OF STRATHCLYDE (GB) | 2023-04-06 | — | — | WO | disclosed |
| US-20150183770-A1 | 5-RING HETEROAROMATIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2015-07-02 | — | — | US | disclosed |
| US-8921406-B2 | 5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-12-30 | — | — | US | disclosed |
| US-20110207788-A1 | 5-Ring Heteroaromatic compounds and their use as binding partners for 5-ht5 receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-08-25 | — | — | US | disclosed |
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
| US-5686484-A | ANTHELMINTICS, ACARICIDES, INSECTICIDES | SANKYO CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0357460-B1 | 13-Substituted milbemycin derivatives, their preparation and use | SANKYO CO (JP) | 1995-01-18 | — | — | EP | disclosed |
| EP-0357460-A2 | 13-Substituted milbemycin derivatives, their preparation and use | Sankyo Company Limited (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | F2 871/4885F10 1154/4885F12 341/4885 |
| US-20150183770-A1 | 5-RING HETEROAROMATIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR3A, HTR6 | F2 4758/4885F10 4110/4885F12 4631/4885 |
| US-20110207788-A1 | 5-Ring Heteroaromatic compounds and their use as binding partners for 5-ht5 receptors | HTR5A, HTR3A, HTR6 | F2 4758/4885F10 4110/4885F12 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.